CEACAM5 and colorectal neoplasm: Tiernan et al. reported EGFR overexpression in only 32.8% of 280 colorectal tumor cases compared to normal tissue, far less consistent than CEA’s 98.8%, underscoring its limited specificity for in vivo targeting [22].